^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    09/20/2017
    Excerpt:
    In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
    Secondary therapy:
    carboplatin + paclitaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    Combination of atezolizumab and bevacizumab with carboplatin and paclitaxel should be considered as a therapeutic option in patients with EGFR-mutated tumour.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    Ann Oncol (2018) 29 (suppl 4): iv192–iv237
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Thorac Oncol
    Title:

    IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

    Published date:
    10/06/2021
    Excerpt:
    Overall, 1202 patients (intention-to-treat [ITT] population) with chemotherapy-naive, metastatic, nonsquamous non-small cell lung cancer were randomized to ABCP, ACP or BCP….At data cutoff (September 13, 2019; median follow-up, 39.3 months), OS improvements were sustained with ABCP versus BCP in sensitizing EGFR mutations (all: hazard ratio [HR] 0.60; 95% CI: 0.31-1.14; prior tyrosine kinase inhibitor [TKI]: HR 0.74; 95% CI: 0.38-1.46) and baseline liver metastases (HR 0.68; 95% CI: 0.45-1.02) subgroups.
    Secondary therapy:
    carboplatin + paclitaxel
    DOI:
    10.1016/j.jtho.2021.09.014
    Trial ID:
    IMpower150
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

    Excerpt:
    ...Stage IIIB or IV NSCLC with known EGFR activating mutation not amenable to curative surgery or radiotherapy...
    Trial ID:
    NCT03647956
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure

    Published date:
    07/16/2021
    Excerpt:
    Combination approach of atezolizumab, bevacizumab, pemetrexed and carboplatin achieved promising efficacy in metastatic EGFR mutated NSCLC after TKI failure.
    Secondary therapy:
    carboplatin + pemetrexed
    DOI:
    10.1016/j.lungcan.2021.07.004
    Trial ID:
    NCT03647956
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2020
    Title:

    A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure

    Published date:
    11/17/2020
    Excerpt:
    ORR was 62.5%. Median PFS was 9.43 month (95% CI: 7.62 – 12.1 months).Combination approach of atezolizumab, bevacizumab, pemetrexed and carboplatin achieved promising efficacy in metastatic EGFR-mutated NSCLC after TKI failure.
    Secondary therapy:
    carboplatin + pemetrexed
    Trial ID:
    NCT03647956